Exelixis, Inc. (EXEL)
| Market Cap | 12.11B +16.2% |
| Revenue (ttm) | 2.38B +3.3% |
| Net Income | 833.42M +29.5% |
| EPS | 3.02 +37.2% |
| Shares Out | 251.36M |
| PE Ratio | 15.93 |
| Forward PE | 14.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,178,996 |
| Open | 46.59 |
| Previous Close | 46.21 |
| Day's Range | 46.46 - 48.17 |
| 52-Week Range | 33.76 - 49.62 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 47.25 (-1.89%) |
| Earnings Date | May 5, 2026 |
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $47.25, which is a decrease of -1.89% from the latest price.
News
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities...
Exelixis price target raised to $56 from $54 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $56 from $54 and keeps a Buy rating on the shares. The firm updated the company’s model post the
Exelixis price target raised to $50 from $49 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $49 and keeps an Equal Weight rating on the shares after the company shared updates across its
Exelixis price target raised to $47 from $44 at Stifel
Stifel raised the firm’s price target on Exelixis (EXEL) to $47 from $44 and keeps a Hold rating on the shares.
Exelixis price target raised to $55 from $51 at TD Cowen
TD Cowen raised the firm’s price target on Exelixis (EXEL) to $55 from $51 and keeps a Buy rating on the shares. The firm said new combo studies for zanza
Exelixis Earnings Call Transcript: Q1 2026
Q1 2026 saw robust revenue and net income growth, record CABOMETYX patient starts, and strong market share gains. ZANZA's NDA for CRC is under review, with multiple pivotal trials advancing across tumor types. A new $750M share repurchase plan was authorized.
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives...
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 ...
Exelixis price target raised to $45 from $44 at Barclays
Barclays raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and targets in the
Exelixis Transcript: Barclays 28th Annual Global Healthcare Conference
CABOMETYX drives strong sales and strategic focus in GI/GU oncology, with Zanzalintinib advancing in pivotal studies and a December PDUFA. Expansion into CRC and NET, disciplined BD, and innovative pipeline assets position the company for continued growth.
Exelixis Transcript: The Citizens Life Sciences Conference 2026
Revenue reached $2.123 billion with guidance for $2.4 billion in 2026, driven by RCC and NET launches. Zanza is positioned for a $5 billion+ opportunity with seven pivotal studies, while STELLAR-303 and -304 aim to set new standards in CRC and non-clear cell RCC.
Exelixis Transcript: Leerink Global Healthcare Conference 2026
Recent ASCO GU data in RCC showed PFS benefit but no significant OS improvement, influencing a shift toward sequential treatment strategies and highlighting the importance of quality of life and toxicity profiles. Key trials like LITESPARK-033 and STELLAR-304 aim to redefine standards in RCC, while STELLAR-303 in CRC demonstrated a survival advantage, supporting strong growth projections for 2026.
Exelixis Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted a strategic shift toward building multiple oncology franchises, with zanzalintinib poised for launch and a robust pipeline targeting RCC, CRC, and other cancers. Strong financial performance, ongoing pivotal trials, and disciplined capital allocation support long-term growth.
Exelixis price target lowered to $43 from $46 at RBC Capital
RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $43 from $46 and keeps a Sector Perform rating on the shares. The firm notes that competitive pressures could
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th...
Exelixis price target raised to $54 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $54 from $52 and keeps a Buy rating on the shares. The firm updated the company’s model post the
Exelixis price target raised to $44 from $43 at Stifel
Stifel raised the firm’s price target on Exelixis (EXEL) to $44 from $43 and keeps a Hold rating on the shares following a Q4 report that held “no surprises” after
Exelixis Earnings Call Transcript: Q4 2025
2025 saw robust revenue and net income growth, led by CABOMETYX's dominance in RCC and neuroendocrine tumors, and preparations for the launch of zanzalintinib in CRC. The company remains focused on expanding its oncology franchises, advancing pivotal trials, and maintaining strong capital allocation.
Exelixis reports Q4 EPS 94c, consensus 81c
Reports Q4 revenue $598.663M, consensus $598.68M. “Exelixis (EXEL) delivered strong results in 2025 and is well positioned for a breakout year in 2026,” said Michael M. Morrissey, Ph.D., President and
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
Exelixis (EXEL) is maintaining the previously provided financial guidance for fiscal year 2026. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential...
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key cor...
Exelixis price target raised to $44 from $41 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $44 from $41 and keeps an Equal Weight rating on the shares as part of a Q4
Exelixis reports zanzalintinib new drug application accepted for review by FDA
Exelixis (EXEL) announced that its new drug application for zanzalintinib, in combination with atezolizumab, has been accepted for review in the U.S. for the treatment of adult patients with metastati...
Exelixis price target raised to $49 from $48 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Exelixis (EXEL) to $49 from $48 and keeps an Equal Weight rating on the shares.
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted ...